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Abstract
Cholesterol-rich domains have been observed to exist in cell membranes under physiological and pathological conditions. Their
compositions and the microenvironment of their formation vary over a wide range. Very little information is however available on the
molecular structure and organization of these domains. The techniques available to provide such structural information are reviewed here
first. The possibility of using tailor-made antibodies as reporters of molecular organization in membranes is then considered. The concept of
antibodies recognizing molecular organization rather than single molecular epitopes is established, reviewing the existing works on antibody
and protein recognition of crystalline molecular arrays. The information that such antibodies could provide in cells is finally examined
together with a proof of application.
D 2003 Elsevier Science B.V. All rights reserved.
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1. Statement of the problem
Until the late 1990s, the classical ‘fluid mosaic’ model
was accepted as the best description of the molecular
organization in cell membranes. In this model, phospholi-
pids and cholesterol molecules constitute the tassels of a
disordered mosaic, in which proteins are embedded, homo-
geneously distributed and freely diffusing. The lipid bilayer
was conceived as a neutral two-dimensional solvent, which
does not interact with the proteins dissolved in it, and only
functions to separate internal from external space.
The possibility of segregation of cholesterol-rich domains
of different composition had been considered in the 1980s to
explain the distribution of cholesterol in the membranes of
eye lens fiber cells, where the cholesterol/phospholipid ratio
reaches values as high as 4 [1]. Such a high ratio required
reconsideration of the fluid mosaic model because choles-
terol is immiscible with phospholipids in those ranges of
composition. Eye lens fiber cells are specialized, terminally
differentiated cells, and the formation of domains in their
membranes may not be representative of other cells. The
basic idea of segregation of distinct domains in the plasma
membrane was however supported by studies performed on
epithelial cells [2]. The plasma membrane of these cells is
polarized into apical and basolateral domains, with the
former domain being enriched in sphingolipids, while the
latter is enriched in phosphatidylcholine.
Once evidence for the existence of organized cholesterol-
rich domains in other cells started to accumulate, the
classical ‘fluid mosaic’ model was definitely questioned.
In 1997, Simons and Ikonen [3] summarized ideas that had
been evolving for a number of years, establishing a new
concept of membrane organization. The central tenet is that
sphingolipids and cholesterol cluster dynamically to form
rafts that move within the lipid bilayer as distinct units. It
was proposed that these rafts function as platforms for the
attachment of proteins when membranes are moved around
inside the cell and during signal transduction.
Involvement of rafts has been implied, to date, in all kinds
of physiological and pathological processes including signal
transduction during the allergic immune response and in the
assembly of immunological synapses [4]. The formation of
amyloid plaques in Alzheimer disease [5], HIV and other
retrovirus assembly and release [6], sperm capacitation [7]
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and platelet activation [8] are just a few other examples where
raft involvement has been indicated. The suggested structural
model of lipid rafts involves a liquid ordered assembly of
sphingolipids associated laterally with one another, with the
voids between the large head-groups filled by cholesterol
molecules. The latter function as spacers between the pre-
dominantly saturated lipid chains, which have a lower cross-
sectional area relative to the large sphingolipid heads [3,9].
Proteins anchored to saturated lipids (such as GPI), specific
transmembrane proteins or proteins that carry hydrophobic
modifications partition into rafts owing to preferential pack-
ing of their membrane anchors. The fluid regions in between
the close packed sphingolipid–cholesterol clusters are occu-
pied by phospholipids.
To date, however, there is no direct structural information
to confirm or disprove the raft model. It would be advanta-
geous to determine some molecular parameters of the
component arrangement within the domains. Do all lipid
rafts have the same molecular organization, and what is this
organization? Are the components juxtaposed in any regular
alternation in the plane of the membrane? Is the distribution
of the components within one domain homogeneous? These
are only a few questions that come to mind, which are
essential to our understanding of the functioning of lipid
rafts and cholesterol-rich domains in general. Once accepted
that cholesterol is not homogeneously distributed in cell
membranes, one would expect a spectrum of different
organization motifs, dependent on cell or domain function,
on cholesterol concentration and on the physiological or
pathological conditions which the cell is experiencing.
The purpose of this report is to review the existing
techniques that have been used or potentially can provide
structural information about organized cholesterol-rich
domains in cell membranes. In particular, the use of speci-
alized antibodies that are capable of two-dimensional and
three-dimensional structural pattern recognition will be con-
sidered.
2. Available techniques for structural characterization of
cholesterol-rich domains in membranes
The number of examples where organized cholesterol-
rich domains were found in cell membranes has enormously
increased within the last few years. Thus, only some
indicative examples will be mentioned here for the purpose
of illustrating the various techniques and the information
that can be derived from them. No attempt will be made at a
comprehensive review of the subject, which is much more
effectively described in the various manuscripts in this
issue. Moreover, all types of cholesterol-rich domains will
be examined within the same framework. Thus, atheroscler-
otic cells or eye lens fiber cells, and cholesterol/sphingolipid
rafts will be considered side by side, disregarding the
differences in composition or the specific conditions of
formation. This is because the conceptual difficulties in de-
termining structural parameters within membranes in living
cells are expected to be basically similar, even in very dif-
ferent environments.
Sphingolipid–cholesterol rafts were first detected because
they are insoluble in the detergent Triton X-100 at 4 jC.
Because of their high lipid content, these detergent-insoluble,
glycolipid-enriched complexes float to a low density during
gradient (sucrose) centrifugation, together with any associ-
ated proteins. The proteins are thus identified as raft-associ-
ated. These same proteins, once identified as raft-associated,
were subsequently exploited to study the spatial distribution,
the size and the properties of rafts through the clustering of
fluorescence, gold or other immunolabels. A wide range of
imaging techniques was used to study rafts [4], including
fluorescence spectroscopy, transmission electron microscopy
(TEM), near-field scanning optical microscopy (NSOM),
atomic force microscopy (AFM) and photonic force micro-
scopy. Each technique has advantages and disadvantages;
each provides information at a different resolution. A few
examples are given below.
Varma and Mayor [10] used fluorescent resonance
energy transfer (FRET) between GPI-anchored proteins in
living cells to show that these proteins are clustered in lipid
domains likely to be smaller than 70 nm, thus explaining
why they cannot be detected by light microscopy.
Friedrichson and Kurzchalia [11] showed that GPI-anch-
ored proteins exist in clusters by using short cross-linkers.
Harder et al. [12] used antibodies against raft-associated
proteins to co-cluster the small rafts into super rafts that
could be detected by light microscopy.
In photonic force microscopy [13] a laser trap is used to
confine the motion of a bead bound to a raft protein through
an antibody. The bead’s fluctuations inside the trapping
potential are tracked with sub-nanometer and microsecond
resolution by high-resolution single particle tracking. The
method measures the viscous damping of the membrane
domain in the lipid bilayer. Considering that raft-associated
protein diffusion is significantly reduced compared to that of
non-raft proteins, the measurements agree with lipid rafts
being cholesterol-stabilized complexes of 26–40 nm in
diameter diffusing as one entity for minutes.
Signaling molecules were localized on the cytoplasmic
face of native membranes by immunogold labeling and
high-resolution TEM [14]. The high affinity IgE receptor,
which is clustered in rafts, and two of its associated
tyrosine kinases were mapped in membrane sheets prepared
from mast cells. One of the kinases was found associated in
small clusters, co-localized with small- and medium-sized
clusters of receptor. The other kinase is dramatically
recruited in large clusters of the receptor. TEM measure-
ments may thus in principle provide some direct informa-
tion about the organization of micro- or nanocrystalline
domains in cell membranes. The option of performing
cryo-microscopy in vitrified samples would furthermore
guarantee the absence of artifacts due to drying of the
biological membrane.
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NSOM [15] exploits the near-field interaction of light
with substrates to image surfaces at resolutions of tens of
nanometers, well beyond the resolution of conventional
light microscopy. NSOM was applied to image the plasma
membrane of skin fibroblasts, using a fluorescently labeled
phospholipid analog and fluorescent antibodies to mem-
brane proteins. Both fluorophores showed the presence of
distinct patches, tens to hundreds of nanometers in size, in
fixed and dried cell membranes.
AFM provides topographic images of surfaces of materi-
als as soft as cells, under liquid, with a lateral resolution of
up to 10 nm. AFM recently provided an interesting con-
tribution to the understanding of the artifacts possibly
arising from detergent extraction of rafts from cell mem-
branes [16]. Observed in situ after Triton X-100 treatment,
the detergent-resistant plasma membrane (DRM) fragments
form domains whose size exceeds 15–20 Am2, orders of
magnitude larger than the largest domains observed in living
cells, strongly suggesting that membrane microdomains
rearrange into larger DRMs during Triton X-100 treatment.
Ocular lens cell plasma membranes were shown to
contain immiscible cholesterol domains, using small angle
X-ray diffraction [17]. Small angle X-ray diffraction
allows the detection of relatively large (nanometer scale)
periodicity in oriented structures. The periodicity of 3.4
nm, characteristic of the cholesterol monohydrate unit cell,
was observed in ocular lens cell plasma membranes.
Spanning the long dimension of two cholesterol mole-
cules, it coincides with the thickness of the membrane in
the direction perpendicular to the bilayer. This demon-
strates that there are domains in the membrane with
structure akin to that of cholesterol monohydrate crystal
structure, at least in that direction. The domains are thus
not only cholesterol-rich, but also close to crystalline, if
not fully crystalline.
The same technique was applied to study the plasma
membrane of smooth muscle cells in cholesterol-fed rabbits,
also showing a periodicity of 3.4 nm [18], and consequently
the presence of crystalline or almost crystalline cholesterol
domains. This is the only technique, among those cited
above, that provided until now real structural information
from in vivo or ex vivo cell membranes.
Clearly, none of these techniques provides any structural
characterization of the lateral organization of the compo-
nents within the cholesterol-rich domains.
Much information, albeit indirect, was derived from
studies performed on membrane models in vitro [19–21].
Much of this is described in other manuscripts in this issue
(Bach and Wachtel, this issue; McConnell, this issue), and
will thus not be detailed here. Only the studies that poten-
tially contain structural information at the molecular level
will be mentioned below.
AFM was used to provide images of cholesterol/sphin-
gomyelin domains in supported bilayers at nanometer res-
olution [22]. The technique can, in principle, provide
images at molecular resolution of crystalline layers.
Another potentially interesting technique that has been
applied in a proof-of-concept type of study is time-of-flight
imaging secondary ion mass spectrometry (TOF-SIMS)
[23]. It involves a unique development of mass spectrometry
for molecule-specific imaging of frozen hydrated samples at
micrometer resolution.
Neutron grazing incidence diffraction (GID) [24] was
used to provide evaluations of the size of domains in model
binary lipid mixtures. The information does not reach yet
the molecular packing level. GID has, however, the very
definite potential to provide molecular level information on
the structural organization of thin films such as membranes.
X-ray GID, combined with X-ray reflectivity, has been
applied to determine the structure of phospholipid mono-
layers [25,26], and recently, the packing arrangement of a
glycosphingolipid–phospholipid monolayer mixture [27].
The nucleation of crystalline films of cholesterol on water
in the presence and absence of phospholipids has been
monitored [28]. The crystallization of cholesterol at the
air–water interface was recently described as the dynamic
formation of an ordered trilayer of cholesterol with structure
akin to that of cholesterol monohydrate, mediated through
the transformation of other less ordered structures [29].
3. Specific antibodies can provide information on the
organization of crystalline layers: proof of concept
Clearly, a complete in situ X-ray structure determination
would be the ultimate goal for those interested in the
molecular organization inside cholesterol-rich domains in
cells. Such a goal is however well beyond our possibilities
for various reasons: the concentration of the domains is low
in most cells (not in eye lens cells or atherosclerotic cells),
their size is in the tens of nanometers and their crystallinity
may well be not high enough to provide interpretable
diffraction signals. Furthermore, the biological milieu is
often difficult to preserve during extraction procedures,
and the X-ray radiation itself may modify the organization
of the microdomains. Thus, reaching this ultimate goal will
require much additional technical development.
With this realization, we have to consider other ap-
proaches, albeit less informative. One conceivable possibility
is to create a battery of molds that are sensitive each to the
molecular organization of one type of domain, by virtue of
shape-complementarity and chemical complementarity to
some or all the components. These ‘‘recognition patterns’’
might then be tested on the arrays, looking for one that fits.
The information on the appropriate mold could then be
directly translated into structural information on the domains
(Fig. 1). With this idea in mind, we embarked 10 years ago in
a series of studies using antibodies as the recognition tool and
crystals as substrates.
It has been repeatedly shown, especially in biominerali-
zation research, that specific structural recognition can occur
between specialized proteins and targeted crystal surfaces
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[30,31]. Interestingly, the recently determined structures of
an antifreeze protein from eel pout and one from a beetle
proved to be highly complementary to the specific surfaces
of ice crystals to which they bind [32,33]. Can a similar
situation arise between antibodies and crystals in patholog-
ical conditions?
There is no good reason to assume that the immune
system should relate to crystals in a manner different from
other invaders because of their intrinsic nature as crystals.
Antibody binding sites generally show a good geometrical
and chemical fit to the surface domains of bound macro-
molecules. This surface-to-surface recognition may occur
with any surface, including crystal surfaces. The substantial
difference between conventional antigens, such as proteins,
and crystal surfaces is that crystals are formed of small
molecules that would not interact with antibodies in a
dispersed solution. When organized in a three-dimensional
array, their surfaces may well be expected to have character-
istics akin to those of a macromolecular surface. In antibody
complexes with protein antigens, the buried interfacial area
typically ranges between 600 and 1000 A˚2 [34]. This would
correspond, in a molecular crystal, to an array of 12–20
molecules with a cross section of 5 10 A˚. The establish-
ment of high affinity interactions would imply the recog-
nition of a repetitive series of molecular moieties in the
correct arrangement.
The use of specific antibodies as reporters of the structure
of organized arrays of small molecules was initiated when
we discovered in the synovial fluid of gout patients the
presence of a population of antibodies that accelerated in
Fig. 1. Schematic representation of the possible complementarity between antibody variable regions (a, b, c, d) and organized crystal surfaces. The arrangement
of the components in the crystal is inspired by the bilayer structure of cholesterol monohydrate. The recognition of the same antibody variable regions for the
specified schematic arrangements is reproduced below, illustrating possible membrane arrangements with molecular organizations similar or identical to those
delimiting the crystal faces.
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vitro the formation of crystals of monosodium-urate mono-
hydrate (MSUM) [35]. To explain these data, MSUM
crystals, which are symptomatically associated with the
disease, were postulated to elicit a specific immune
response, rather than the general inflammation that was
believed to be involved in the response of the organism to
the crystals.
In order to characterize the molecular nature of the
antibody–crystal interactions, we subsequently isolated
monoclonal antibodies that interact strongly with crystals
of cholesterol monohydrate and dinitrobenzene [36], and
recently of the tripeptide leucine–leucine–tyrosine [69].
Two of the antibodies that selectively interact with
cholesterol monohydrate crystals were studied in depth
[37]. One of these, antibody 36A1, was shown to interact
preferentially with one set of faces in the cholesterol
crystals. These faces are characterized by long hydrophobic
stretches exposing the cholesterol backbones, separated by
hydrophilic steps where water molecules and the 3h-
hydroxyls of the cholesterol molecules emerge. The second
antibody, 58B1, is highly specific to cholesterol monohy-
drate crystals. It interacts with more than one set of crystal
faces, all exposing the hydrophobic backbone and the
hydrophilic hydroxyls of cholesterol in various arrange-
ments. Most importantly, neither antibody interacts or
recognizes the isolated cholesterol molecule, which exposes
a surface completely different from that exposed by the
array of moieties at the cholesterol crystal surfaces. The
variable regions of the two antibodies, as well as of anti-
bodies specific to other crystals were sequenced, and the
structures of their binding sites were modeled [38]. The
model is highly reliable for antibody 36A1 because its
problematic H3 loop is very short and rigid. It is less
defined for antibody 58B1, which has an extremely long
H3 loop and is consequently supposed to be more flexible.
Docking of the step-shaped binding site model of antibody
36A1 on the molecular step of the recognized face resulted
in an excellent geometrical and chemical match with cho-
lesterol hydroxyls and hydrophobic cholesterol backbones,
respectively (Fig. 2).
We subsequently showed that both antibodies interacting
specifically with cholesterol crystals are able to recognize
cholesterol arrays organized in the form of monolayers at
the air–water interface, while antibodies that are not spe-
cific to cholesterol crystals do not [39]. In monolayers, the
cholesterol molecules are aligned with each other in an
arrangement geometrically akin both to that of cholesterol in
the crystal structure and in cell membrane bilayers. More-
over, antibody 36A1 does not interact with monolayers of
epicholesterol, showing fine stereochemical/structural dis-
crimination between arrays of isomeric steroids [40]. The
antibody affinity to the cholesterol monolayers is so high
that labeling by the antibody is observed in equilibrium with
a residual concentration in solution at least as low as 10 11
M [41]. It is evident that stereochemical recognition oper-
ates at interfaces of organized surfaces as well as, or even
better than, on separated molecules.
Within the above conceptual framework, it is interesting
to consider whether the anti-cholesterol antibodies reported
in the literature are responsive to cholesterol molecules or to
cholesterol arrays. Anti-cholesterol antibodies were first
reported in 1988 by Swartz et al. [42], after immunizing
mice with liposomes containing 71% cholesterol, together
with lipid A as adjuvant. They were isolated by their ability
to react with liposomes containing 71% cholesterol, but not
with liposomes containing 43% cholesterol. The antibodies
were reported to bind to cholesterol crystals [42]. Naturally
occurring autoantibodies to cholesterol were subsequently
reported in miniature pigs [43] and humans [44]. The
apparent paradox of antibodies being raised against a self-
molecule could be satisfied if the antibodies were generated
not against isolated cholesterol molecules, but against
molecular arrays that are not present at the time when the
immune system is defined.
The concept of antibodies as reporters of molecular
organization is assuming more and more credibility. In a
Fig. 2. Proposed docking models for (a) antibody 36A1 on the cholesterol monohydrate crystal surface that it recognizes. Blue, cholesterol backbone in the
crystal; cyan, hydroxyl groups of cholesterol; orange, water molecules; brown, model of the antibody variable region, with the hydrophilic and hydrophobic
regions in the binding-site color-matched to the respective epitope targets. (b) Antibody 122B1 on the dinitrobenzene crystal surface that it recognizes. Blue,
aromatic ring; orange, N and red, oxygen of the nitro-group; grey, model of the antibody variable region with the aromatic and polar groups in the binding-site
color-matched to the respective epitope targets. The shape complementarity is accompanied in both cases by chemical complementarity between the amino acid
side-chains of the antibody and the functional groups of the recognized surfaces. The two models of antibodies, 122B1 and 36A1, are similar to the
arrangements schematically represented in Fig. 1 by (b) and (a), respectively. An additional antibody, specific to crystals of the tripeptide leucine– leucine–
tyrosine, has been found whose model is very similar to that represented in Fig. 1 by (d) [69].
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very recent manuscript, O’Nuallain and Wetzel report the
isolation of antibodies that bind an Alzheimer peptide in its
amyloid fibril state, but not in its soluble, monomeric state
[45].
In principle, one could thus imagine to generate different
specific antibodies against epitopes of known organization,
characterize them in the artificial system and then use them
as reporters of different organizations of cholesterol and
other components in cells, as suggested at the beginning of
the section.
The extant question is whether the antibodies can be used
in cells. The following section is a proof of application.
4. Application of specific antibodies to the detection of
cholesterol-rich domains in cells
The application of anti-cholesterol monoclonal antibod-
ies to the detection of cholesterol in cells could present new
opportunities for learning about the trafficking and function-
ing of cellular cholesterol, besides its organization. Agents
for the detection of cholesterol in cells include filipin, a
polyene antibiotic, digitonin, a saponin, and thiol-activated
cytolysin toxin polypeptides [46–51]. Each reagent binds to
unesterified cholesterol, reacting with the 3h-hydroxyl
group on cholesterol, and has been successfully used to
localize cholesterol in cells. The use of digitonin is problem-
atic in that the detergent properties of this agent tend to
extract cholesterol from cells contemporaneous to binding
it, forming insoluble crystalline complexes that can be
identified with the electron microscope. Filipin has been a
very useful probe of cellular cholesterol that can be visual-
ized with both fluorescence and electron microscopy. Filipin
shows extensive labeling of plasma membrane and intra-
cellular cholesterol. However, filipin does not detect choles-
terol in clathrin-coated regions of the plasma membrane,
possibly due to steric hindrance from the clathrin coat on
these vesicles [52].
Anti-cholesterol monoclonal antibodies have been suc-
cessfully applied to label cholesterol in crystals, liposomes
and plasma lipoproteins [42,53]. One limitation of anti-
cholesterol antibodies in their possible use to label choles-
terol in cultured cells is that while they are expected to label
plasma membrane cholesterol, they cannot be readily used
to label intracellular cholesterol. This is because immuno-
globulin proteins do not penetrate an intact plasma mem-
brane, as do the much smaller cholesterol probes filipin
(m.w. 655) and digitonin (m.w. 1229). To allow penetration
of antibodies, the plasma membrane must be permeabilized.
This is usually done by extracting lipids from the plasma
membrane with solvents such as acetone, ethanol, methanol
or detergents such as Triton X-100. Of course, these
permeabilizing agents will extract or significantly disturb
cholesterol in the cell. However, it is possible to label
cryosections prepared from frozen cells or tissue as a means
to access the intracellular space without permeabilizing the
cell. Recently, this has been done for the labeling of intra-
cellular cholesterol with a cholesterol-binding toxin and an
anti-cholesterol antibody [54,55].
The interaction of an anti-cholesterol antibody with
cholesterol in the plasma membrane of a cell would be
expected to be limited to one specific condition of choles-
terol molecules. An antibody that reacts with a defined
epitope on the cholesterol molecule would not be expected
to easily detect cholesterol in the plasma membrane because
there, cholesterol associates closely with phospholipids. It is
thus likely that under most circumstances the cholesterol
epitopes would not be exposed sufficiently to react with a
nonpenetrating molecule such as IgM [56].
We found that antibody 58B1, which was selected for its
reactivity with cholesterol monohydrate crystals, does not
react with the surface of cultured cells such as macrophages
and fibroblasts under normal conditions. It is only when the
plasma membrane is enriched with cholesterol that this
antibody shows reactivity with the cell surface [57]. Max-
imal cholesterol labeling occurs when fibroblasts or macro-
phages are incubated with low-density lipoprotein (LDL) or
acetylated LDL, respectively, as a source of cholesterol.
With this cellular cholesterol enrichment, antibody 58B1
shows labeling of the plasma membrane. These cells take up
LDL and acetylated LDL by receptor-mediated endocytosis
that transports these lipoproteins to lysosomes [58]. The
lipoproteins are degraded in the lysosomes releasing unes-
terified cholesterol. Some cholesterol traffics to the plasma
membrane and to intracellular membranes, the latter where
acyl-CoA:cholesterol acyltransferase (ACAT) esterifies the
cholesterol for storage in cellular lipid droplets [59]. Phar-
macological inhibition of ACAT causes further buildup of
unesterified cholesterol within intracellular and plasma
membranes. With ACAT inhibition, the intensity of anti-
body 58B1 plasma membrane labeling and the number of
cells labeled are greater than when cells are incubated with
lipoproteins without ACAT inhibition.
The pattern of antibody 58B1 labeling is punctate (Fig.
3), suggesting the presence of cholesterol microdomains, the
predicted epitope requirement for reactivity of this antibody.
This staining pattern is very different from that of filipin,
which shows a diffuse staining of the plasma membrane,
consistent with the more widespread distribution of isolated
cholesterol molecules that this smaller penetrating choles-
terol probe can label. In addition to labeling of plasma
membrane cholesterol microdomains, antibody 58B1 also
labels small extracellular particles surrounding macro-
phages. These stained extracellular particles could be shed
plasma membrane microdomains or other forms of choles-
terol excreted by the cultured cells.
When labeling any antigen with antibody, it is necessary
to show that the labeling is specific; in the present case, it is
necessary to show that cholesterol microdomains are
detected. Specificity of cholesterol staining can be inferred
from a number of control tests. For antibody 58B1 labeling
of cells [57], the labeling could be eliminated when cellular
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cholesterol was removed from the plasma membrane by
incubation with cholesterol acceptors such as HDL or
cyclodextrin, or by extraction with organic solvents such
as methanol. Oxidative modification of the 3-h-OH group
on cholesterol by exposure of cells to cholesterol oxidase
also eliminated labeling, presumably because of the impor-
tance of this group for preserving epitope structure
[49,60,61]. Lastly, the cholesterol microdomains labeled
by antibody 58B1 responded to agents that modulate cho-
lesterol trafficking in living cells. Mainly, plasma membrane
labeling was decreased when cells were treated with keto-
conazole, an agent that impairs trafficking of cholesterol
from lysosomes to the plasma membrane. Plasma membrane
labeling also was decreased in mutant NPC fibroblasts with
a known defect in trafficking of cholesterol from lysosomes
to plasma membrane. Thus, antibody 58B1 detects a plasma
membrane pool of cholesterol, responsive to agents that
modulate cholesterol trafficking to and from the plasma
membrane.
Not all antibodies raised and selected against cholesterol
crystals may meet these types of specificity tests. Antibody
36A1, which has been characterized much more extensively
(see Section 3), shows extensive labeling of cellular plasma
membranes even when these membranes are not enriched
with cholesterol. Concomitantly, cyclodextrin-mediated
removal of cholesterol from the plasma membrane [57,62]
did not eliminate labeling by antibody 36A1 (unpublished
data). Neither did treatment of the test cells with cholesterol
oxidase decrease antibody 36A1 labeling. Thus, we con-
clude that this antibody detects something, in addition to
cholesterol, that occurs in the plasma membrane of cells.
This behavior is in agreement with experiments performed
on monolayers of triacontanol, an alcohol with a long
saturated aliphatic chain, where labeling with antibody
36A1 was observed, albeit with a much lower affinity than
cholesterol [41].
The exact structural nature of the plasma membrane
cholesterol microdomains detected by antibody 58B1
remains to be determined. However, the characteristics of
antibody 58B1 binding to cholesterol crystals and mono-
layers, but not to isolated molecules, guarantee that the
recognized epitope is organized in crystalline-like micro-
domains [63]. Such cholesterol microdomains form in
model membranes when the membranes are enriched with
cholesterol [18,64–67]. However, the detergent-insoluble
lipid microdomains enriched in sphingomyelin and choles-
terol, associated with rafts and caveolae, presumably have a
different structure. Accordingly, the cholesterol microdo-
mains we detected in the plasma membrane with antibody
58B1 were sensitive to extraction with ice-cold 1% Triton
X-100, while lipid rafts and caveolae are not extracted under
these conditions. In conclusion, the conceptual procedure of
applying antibodies, raised and isolated against crystals, to
detect the same or similar arrangements in cells is opera-
tional, provided caution is applied in the interpretation of the
results especially in relation to the uniqueness of the
detected epitope.
Because of the epitope specificity of antibodies, the
potential exists for the development of new monoclonal
antibodies that can detect other pools of cholesterol within
the plasma membrane. It may be possible to expand the
reactivity of cholesterol antibody 58B1 with cells by enzy-
matically digesting phospholipids in the plasma membrane,
thereby unmasking additional cholesterol labeling [68].
Antibody 58B1 should be generally useful for studying
gene products that regulate cholesterol trafficking and efflux
in cells. For example, because antibody 58B1-labeled cho-
lesterol microdomains do not form in mutant NPC fibro-
blasts [57], this antibody could be useful in screening for
drugs that normalize defective cholesterol trafficking in
these cells.
5. Concluding remarks
The existence of cholesterol-rich microdomains in cell
membranes is well established and accepted. Very little
information is however available yet on the molecular
Fig. 3. Antibody labeling of plasma membrane cholesterol microdomains in cholesterol-enriched fibroblasts. Normal fibroblasts were grown following a
procedure that enriches the fibroblasts with unesterified cholesterol, fixed, and labeled with anti-cholesterol antibody 58B1. A biotinylated secondary antibody
coupled with fluorescently labeled avidin was used for detection. Fluorescence (a) and phase (b) photomicrographs of the same microscopic field are shown.
Bar: 20 Am. Reproduced from Ref. [57].
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structure and organization of these domains. Even the most
sophisticated structural techniques, which provide informa-
tion on thin films, cannot yet be readily applied to cells in
vivo or even to membranes ex vivo. The possibility of using
tailor-made antibodies as reporters of molecular organiza-
tion in membranes is suggested. These antibodies could be
raised and selected against specific molecular organizations
of cholesterol, or complexes of cholesterol with sphingoli-
pids or other plasma membrane components. It might thus
be conceivable to create a library of antibodies, each
recognizing different and well-characterized organized
arrays. The functioning of these antibodies would not be
conceptually different from that of conventional antibodies,
besides their performing pattern recognition on a family of
targets, which may have identical composition, but differ
from each other by their organization.
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